Cancers 2010, 2(1), 88-113; doi:10.3390/cancers2010088
Review

Targeted Therapies in Epithelial Ovarian Cancer

email, email and * email
Received: 18 January 2010; in revised form: 2 February 2010 / Accepted: 11 February 2010 / Published: 23 February 2010
(This article belongs to the Special Issue Biomarkers: Oncology Studies)
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Abstract: Molecularly targeted therapy is relatively new to ovarian cancer despite the unquestionable success with these agents in other solid tumours such as breast and colorectal cancer. Advanced ovarian cancer is chemosensitive and patients can survive several years on treatment. However chemotherapy diminishes in efficacy over time whilst toxicities persist. Newer biological agents that target explicit molecular pathways and lack specific chemotherapy toxicities such as myelosuppression offer the advantage of long-term therapy with a manageable toxicity profile enabling patients to enjoy a good quality of life. In this review we appraise the emerging data on novel targeted therapies in ovarian cancer. We discuss the role of these compounds in the front-line treatment of ovarian cancer and in relapsed disease; and describe how the development of predictive clinical, molecular and imaging biomarkers will define the role of biological agents in the treatment of ovarian cancer.
Keywords: ovarian cancer; targeted therapy
PDF Full-text Download PDF Full-Text [177 KB, uploaded 23 February 2010 16:52 CET]

Export to BibTeX |
EndNote


MDPI and ACS Style

Dean, E.; El-Helw, L.; Hasan, J. Targeted Therapies in Epithelial Ovarian Cancer. Cancers 2010, 2, 88-113.

AMA Style

Dean E, El-Helw L, Hasan J. Targeted Therapies in Epithelial Ovarian Cancer. Cancers. 2010; 2(1):88-113.

Chicago/Turabian Style

Dean, Emma; El-Helw, Loaie; Hasan, Jurjees. 2010. "Targeted Therapies in Epithelial Ovarian Cancer." Cancers 2, no. 1: 88-113.

Cancers EISSN 2072-6694 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert